SVA [SINOVAC BIOTECH] 6-K: Sinovac Initiates Dosing in Human Clinical Trial of

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2009-08-27
Original SEC Filing: Click here


Webplus: SVA/20090827/6-K/2_EX-99.1/000.htm SEC Original: sinovacexh99_1.htm
Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1) BEIJING, July 22 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, today announced that it has initiated dosing today in its clinical trial of various Panflu vaccine candidates for pandemic influenza A (H1N1). Results are expected in September 2009.




Webplus: SVA/20090827/6-K/1/000.htm SEC Original: sinovac6k072209.htm
FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4



Company Information:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2009-08-27CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD
BEIJING 100085

Home Page Forums

By | 2016-03-24T05:01:46+00:00 August 27th, 2009|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments

About the Author:

Leave A Comment

Skip to toolbar